Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TLL-018 in Moderate to Severe Plaque Psoriasis
NCT05342428Phase 1Completed
- Sponsor
- Hangzhou Highlightll Pharmaceutical Co., Ltd.
- Start
- Jun 2022
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of girocitinib in plaque psoriasis (4 arms), sponsored by Hangzhou Highlightll Pharmaceutical Co., Ltd. Primary endpoints: Treatment-emergent Adverse Events at 12 weeks, Blood Pressure, Pulse, Respiratory Rate, Temperature at 12 weeks and 3 more. Started Jun 2022; status: completed.
02
Drugs
girocitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT05342428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05342428.